# An experimental drug from Revolution Medicines has shown promising trial results.

*biotech · news · 2026-05-07 · Devdiscourse*

## Key points

- Revolution Medicines' experimental drug daraxonrasib nearly doubled survival for pancreatic cancer patients in trials.
- Argentina's health ministry will test rodents in Ushuaia after a hantavirus outbreak linked to a cruise ship.
- The CDC is monitoring U.S. passengers after the hantavirus incident involving Dutch travelers reported by the WHO.
- CVS Health raised profit forecasts following effective medical cost controls and stronger first-quarter earnings.
- Eli Lilly will invest an additional $4.5 billion in Indiana for new weight-loss drug production.

**Companies:** CVS Health, Eli Lilly, Revolution Medicines
**Countries:** Argentina, United States, Netherlands

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3899485-health-news-roundup-hantavirus-outbreak-on-cruise-ship-and-drug-advancements)

---

Canonical: https://newsio.io/n/2e190a1a-699b-49b4-9710-7249adaae624/an-experimental-drug-from-revolution-medicines-has-shown-promising-trial-results
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works